1. Introduction

A Deferred Prosecution Agreement (DPA) is a legal arrangement between a pharmaceutical company and a prosecuting authority under which criminal prosecution is temporarily suspended, subject to the company's fulfilment of specified legal and compliance obligations.

DPAs are particularly important in the pharmaceutical industry because pharmaceutical companies operate in highly regulated environments involving drug development, clinical trials, marketing, product safety, healthcare professionals, government procurement and international distribution.

A pharmaceutical company may face criminal investigation for:

Illegal promotion of medicines and off-label marketing.

Bribery of doctors and healthcare professionals.

False clinical-trial data.

Fraudulent drug pricing and reimbursement claims.

Foreign bribery and corruption.

Manufacturing violations and falsification of quality records.

Misleading statements concerning drug safety.

Violations of anti-money-laundering and sanctions laws.

Instead of immediately proceeding to a criminal trial, prosecutors may agree to defer prosecution if the company accepts responsibility, pays financial penalties, cooperates with investigators and implements effective compliance reforms.

The central objective is to balance corporate accountability, public health protection, deterrence and the continuity of legitimate pharmaceutical operations.

2. Meaning and Legal Nature of a DPA

A DPA is generally a negotiated prosecutorial arrangement rather than an ordinary civil settlement.

Under a typical agreement, the pharmaceutical company undertakes to:

Accept responsibility for specified misconduct.

Pay criminal penalties or disgorgement where applicable.

Cooperate with regulatory and criminal investigations.

Improve its internal compliance programme.

Establish independent monitoring where required.

Preserve documents and disclose relevant evidence.

Avoid further violations during the agreement period.

If the company fulfils its obligations, the prosecution may be dismissed or not pursued, according to the agreement and applicable law.

If the company breaches the agreement, prosecutors may resume criminal proceedings.

Important distinction: A DPA does not necessarily mean that the company has been convicted. However, it does not automatically eliminate civil liability, regulatory sanctions, product liability claims or individual criminal liability.

3. Why DPAs Are Important in Pharmaceutical Regulation

Pharmaceutical misconduct can affect thousands or millions of patients. Therefore, prosecutors must consider more than financial loss.

For example, if a company illegally promotes a prescription medicine for an unapproved use, the misconduct may create serious public-health risks.

Similarly, bribery of doctors can distort prescribing decisions and undermine patient confidence in medical institutions.

DPAs provide a mechanism for addressing such misconduct while requiring companies to improve their future conduct.

Their importance includes:

Corporate accountability: Companies must accept responsibility for unlawful conduct.

Patient protection: Compliance reforms can improve drug safety and marketing practices.

Regulatory cooperation: Companies must provide information to investigating authorities.

Institutional reform: Internal reporting, auditing and governance systems can be strengthened.

Economic stability: Avoiding immediate corporate collapse may protect employees, research programmes and medicine supplies.

4. Important Case Laws on DPAs in Pharmaceutical Cases

The United States provides particularly important examples of pharmaceutical-sector DPAs. The following cases demonstrate how prosecutors use deferred prosecution to address cartel conduct, competition violations and corporate compliance failures.

Case 1: United States v. Apotex Corp. (2020)

Court/Authority: United States Department of Justice, Antitrust Division.

Facts: Apotex Corp., a pharmaceutical manufacturer, was investigated for alleged criminal price-fixing conduct in the pharmaceutical industry.

The DOJ entered into a Deferred Prosecution Agreement with Apotex on 6 May 2020.

Legal significance:

Demonstrated that DPAs can be used to address criminal antitrust violations in pharmaceutical manufacturing.

Reinforced corporate cooperation as an important component of negotiated criminal resolutions.

Highlighted the importance of competition-law compliance in generic-drug markets.

Principle: Pharmaceutical companies may face deferred prosecution arrangements for competition-related misconduct, subject to agreed conditions.

United States Department of Justice

Case 2: United States v. Sandoz Inc. (2020)

Authority: US Department of Justice, Antitrust Division.

Facts: Sandoz Inc., a pharmaceutical manufacturer, entered into a DPA on 2 March 2020 in connection with criminal allegations involving bid-rigging, market allocation and price-fixing.

Legal significance:

This matter illustrates how competition violations in the pharmaceutical industry can become criminal matters.

The agreement demonstrated the importance of:

Transparent pricing policies.

Independent competition compliance.

Prevention of collusion between competing manufacturers.

Effective internal reporting systems.

Principle: Pharmaceutical manufacturers cannot use market arrangements or coordination with competitors to undermine competition in generic medicines.

United States Department of Justice

Case 3: United States v. Teva Pharmaceuticals USA Inc. and Glenmark Pharmaceuticals Inc. (2023)

Authority: US Department of Justice, Antitrust Division.

Facts: Teva and Glenmark were involved in criminal proceedings concerning alleged conspiracies to suppress competition through price-fixing, customer allocation and bid-rigging in generic medicines.

The companies entered into DPAs dated 21 August 2023.

The allegations concerned generic medicines, including pravastatin, and conduct occurring between 2013 and 2015.

Legal significance:

This is an especially significant example because it demonstrates the application of DPAs to major pharmaceutical manufacturers.

The agreements addressed the following concerns:

Protection of competition in generic medicines.

Corporate accountability for antitrust misconduct.

Implementation of compliance reforms.

Prevention of future collusive conduct.

Protection of consumers against artificially manipulated pharmaceutical prices.

An important issue was the potential impact of criminal convictions on eligibility to participate in US federal healthcare programmes.

The DOJ considered the possibility that conviction could trigger mandatory exclusion and cause serious consequences for customers and employees.

Principle: Prosecutors may consider the wider public-health and healthcare-market consequences of corporate prosecution when determining an appropriate resolution.

United States Department of Justice+1

5. Important Judicial Decisions Governing DPAs

Not every important DPA judgment concerns a pharmaceutical company. Nevertheless, several decisions establish the general legal principles applicable to pharmaceutical corporate prosecutions.

A. United States v. Fokker Services B.V. (2016), 818 F.3d 733

Court: US Court of Appeals for the District of Columbia Circuit.

Facts: Fokker Services entered into a DPA relating to alleged violations of US sanctions and export-control laws.

The agreement required cooperation and implementation of a compliance programme.

Judgment: The Court of Appeals held that the judiciary could not use its authority under the Speedy Trial Act to second-guess the Executive Branch's charging decisions in the manner attempted by the district court.

Relevance to pharmaceutical companies:

This decision is important where pharmaceutical companies face international sanctions, export-control violations or cross-border regulatory investigations.

It illustrates the importance of prosecutorial discretion in corporate criminal settlements.

B. United States v. HSBC Bank USA, N.A. (2017), 863 F.3d 125

Court: US Court of Appeals for the Second Circuit.

Facts: HSBC entered into a DPA concerning alleged failures involving anti-money-laundering controls and sanctions compliance.

Judgment: The court examined the extent of judicial authority to supervise a DPA after its approval.

Relevance to pharmaceutical companies:

The decision is relevant to corporate compliance programmes involving international payments, distributors, intermediaries and transactions with healthcare professionals.

It demonstrates that judicial supervision of DPAs has legal limits and that prosecutorial authorities retain substantial discretion.

6. Legal Framework in the United Kingdom

The United Kingdom introduced its DPA framework through Schedule 17 of the Crime and Courts Act 2013.

The framework became operational on 24 February 2014.

Under this framework, the Serious Fraud Office (SFO) and Crown Prosecution Service can enter into DPAs with eligible organisations.

The principal requirements are:

The agreement must serve the interests of justice.

Its conditions must be fair, reasonable and proportionate.

A judge must approve the agreement.

The organisation must comply with the agreed conditions.

A UK DPA may involve financial penalties, compensation, cooperation, compliance reforms and monitoring.

An important distinction is that UK DPAs are restricted to organisations and do not protect individual directors or employees from prosecution.

GOV.UK

Relevant comparative case: Director of the Serious Fraud Office v. Rolls-Royce plc (2017).

Although not a pharmaceutical case, this decision is relevant to multinational pharmaceutical corporations because it demonstrates how a corporate DPA can address bribery involving international agents and intermediaries.

It provides guidance on:

Corporate self-reporting.

Cooperation with investigators.

Financial penalties.

Compliance improvements.

Individual accountability.

There is an important limitation: the published UK SFO DPA collection does not identify a pharmaceutical-company DPA among its listed agreements. Therefore, the US pharmaceutical agreements provide more direct industry-specific examples.

GOV.UK+1

7. Deferred Prosecution Agreements and Pharmaceutical Compliance

Pharmaceutical companies seeking DPAs must generally demonstrate substantial improvements in their internal governance systems.

The following areas are particularly important.

A. Anti-bribery compliance

Companies must prevent unlawful payments to doctors, hospitals, government officials and procurement authorities.

B. Clinical-trial integrity

Companies must maintain accurate research records and prevent manipulation of clinical-trial results.

C. Marketing compliance

Companies must ensure that pharmaceutical promotion complies with approved indications and applicable advertising restrictions.

D. Manufacturing compliance

Companies must maintain manufacturing quality, testing and documentation systems.

E. Whistleblower protection

Employees should have safe mechanisms to report misconduct without retaliation.

F. Third-party due diligence

Distributors, consultants, marketing agents and overseas representatives should undergo appropriate risk assessment.

These reforms are important because a DPA should not merely resolve past misconduct; it should reduce the likelihood of future violations.

8. Deferred Prosecution Agreements in India

India does not currently have a comprehensive statutory Deferred Prosecution Agreement framework equivalent to the US or UK systems.

However, pharmaceutical companies operating in India may face several forms of criminal and regulatory proceedings.

Important legislation includes:

Drugs and Cosmetics Act, 1940: Regulates drug manufacturing, quality, distribution and sale.

Drugs and Cosmetics Rules, 1945: Establishes detailed requirements concerning drug regulation and licensing.

Prevention of Corruption Act, 1988: Addresses bribery involving public servants.

Competition Act, 2002: Prohibits anti-competitive agreements and abuse of dominant position.

Companies Act, 2013: Provides mechanisms for compounding certain corporate offences.

Bharatiya Nagarik Suraksha Sanhita, 2023: Contains provisions concerning plea bargaining.

Important distinction: Compounding of offences and plea bargaining are not identical to a DPA. They do not establish a general mechanism allowing pharmaceutical corporations to suspend prosecution in exchange for a corporate compliance programme.

Indian legal considerations

A pharmaceutical company accused of manufacturing substandard medicines, fraudulent labelling, bribery or illegal marketing may face criminal prosecution and regulatory action.

Authorities may also take action against responsible directors, officers and other individuals, depending on the applicable statutory provisions.

The absence of a general DPA framework means that companies cannot assume that voluntary disclosure or cooperation will automatically prevent prosecution.

9. Corporate Liability and Individual Accountability

One of the most significant issues in pharmaceutical DPAs is determining whether corporate misconduct should also result in individual prosecution.

For example, a pharmaceutical company may have paid unlawful incentives to healthcare professionals through its marketing department.

The legal investigation may involve:

The pharmaceutical company.

The chief executive officer.

Compliance officers.

Sales and marketing executives.

Regional managers.

Third-party distributors.

External consultants.

A corporate DPA does not automatically grant immunity to these individuals.

Individual liability depends on their participation, knowledge, intent and the applicable criminal legislation.

This distinction is essential because corporate settlements should not become a mechanism for protecting senior executives who knowingly authorised illegal conduct.

10. Advantages of DPAs in Pharmaceutical Cases

1. Protection of patients

A negotiated resolution can require companies to improve manufacturing and quality-control procedures.

2. Financial accountability

Companies may be required to pay substantial penalties, disgorgement and compensation.

3. Regulatory cooperation

DPAs encourage companies to disclose misconduct and assist investigators.

4. Corporate governance

They can require stronger internal auditing, compliance training and independent monitoring.

5. Business continuity

Avoiding a criminal conviction may prevent severe collateral consequences, including disruption of pharmaceutical supplies and healthcare-programme participation.

6. International enforcement

DPAs can help authorities address complex cross-border corporate misconduct involving subsidiaries, distributors and international intermediaries.

11. Criticism and Legal Challenges

Despite their advantages, DPAs have attracted considerable criticism.

A. Weak deterrence

Large pharmaceutical corporations may consider financial penalties merely a cost of doing business.

B. Lack of individual prosecution

Corporate agreements may fail to adequately address the responsibility of executives and senior managers.

C. Transparency concerns

Confidential negotiations can create doubts about fairness and equal treatment.

D. Patient compensation

Financial penalties paid to governments do not necessarily compensate patients harmed by defective medicines.

E. Repeated misconduct

Companies may enter into multiple settlements without sufficiently changing their corporate culture.

F. Unequal treatment

Smaller pharmaceutical manufacturers may not possess the financial resources to negotiate agreements comparable to those available to multinational corporations.

12. Essential Elements of an Effective Pharmaceutical DPA

An effective agreement should contain the following safeguards:

A particularly important requirement is that pharmaceutical compliance monitoring should cover both financial misconduct and patient-safety risks.

For example, a company involved in falsifying clinical-trial information should not be permitted to satisfy its DPA merely by improving financial auditing procedures. Its scientific research, data integrity and patient-protection systems must also be examined.

13. Future Developments and Regulatory Recommendations

The pharmaceutical industry increasingly operates across national borders. A single investigation may involve drug manufacturing in India, clinical trials in Europe, marketing in the United States and distribution in several other countries.

Consequently, DPA systems should develop stronger international cooperation mechanisms.

Important reforms include:

Cross-border information-sharing between pharmaceutical regulators.

Consistent corporate liability standards.

Stronger protection for whistleblowers.

Independent pharmaceutical compliance monitoring.

Mandatory disclosure of serious patient-safety violations.

Better coordination between criminal prosecutors and medicines regulators.

Clear rules preventing corporate agreements from obstructing individual prosecutions.

For India, consideration of a carefully designed corporate DPA framework could provide an additional mechanism for addressing serious corporate economic offences. However, public-health violations, deliberate falsification of safety data and serious patient harm would require particularly strong safeguards against inappropriate settlement.

14. Conclusion

Deferred Prosecution Agreements represent an important development in modern corporate criminal enforcement. In the pharmaceutical industry, they provide a mechanism for addressing price-fixing, bribery, fraudulent marketing and other forms of corporate misconduct.

The cases involving Apotex, Sandoz, Teva and Glenmark demonstrate the practical use of DPAs in pharmaceutical competition enforcement.

However, DPAs should not become instruments through which powerful pharmaceutical companies purchase immunity from serious misconduct. Their legitimacy depends on meaningful financial penalties, transparent judicial oversight, effective compliance reforms, patient protection and individual accountability.

Ultimately, the purpose of a pharmaceutical DPA should be to ensure that corporate wrongdoing is corrected, public health is protected and future violations are prevented.

15. Important Case Law and Legal Reference List

Primary legal references:

US Department of Justice, Antitrust Division: Apotex DPA case.

Sandoz DPA case.

Teva and Glenmark DPA proceedings.

UK Crime and Courts Act 2013, Schedule 17.

UK Serious Fraud Office – DPA judgments and agreements.

Liz Campbell, Revisiting and Re-Situating Deferred Prosecution Agreements in Australia: Lessons from England and Wales (2021) 43(2) Sydney Law Review 187.

The University of Sydney+1

Research note: The Apotex, Sandoz, Teva and Glenmark matters are direct pharmaceutical-sector DPA examples. Fokker and HSBC are general corporate DPA judicial precedents, not pharmaceutical cases. This distinction is important in academic and legal writing.